Management raised full-year 2025 total revenue guidance to $400 million–$415 million and exome/genome revenue growth guidance to 48%–52%, with expected exome and genome revenue of $345 million–$355 ...

That earnings report, unveiled well before market open that day, revealed that GeneDx booked nearly $103 million in revenue.

On July 11, 2025, Kevin Feeley, Chief Financial Officer of GeneDx Holdings ( WGS -1.14%), reported the sale of 5,278 shares of the company in multiple transactions, reducing his post-transaction ...

GeneDx Holdings Corp. WGS is slated to report second-quarter 2025 results on July 29, before the market opens. The renowned genetic testing company reported first-quarter adjusted earnings of 28 cents ...